A Phase 2, Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Dose-Response, Parallel-Group Study of SY-201 Ophthalmic Solution Versus Vehicle Control in Subjects With Dry Eye Disease
Latest Information Update: 28 Nov 2024
At a glance
- Drugs SY-201 (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Seinda Pharmaceutical
- 20 Nov 2023 Status changed from recruiting to completed.
- 27 Jul 2022 Planned End Date changed from 30 Jun 2023 to 25 Jul 2023.
- 27 Jul 2022 Planned primary completion date changed from 30 Jun 2023 to 25 Jul 2023.